SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidias selloff is being tied to the boards investigation into CEO Jensen Huangs relationship with a business executive suspected of Chinese intelligence ties, raising concerns about governance, export-control exposure, and whether Huang could leave. Traders are split between expecting further downside while the investigation unfolds and viewing the drop as an overreaction or buying opportunity, with some pointing to Nvidias AI-chip demand and upcoming earnings.

Digital Turbine, Inc. engages in mobile growth platform solutions for advertisers, publishers, carriers, and device original equipment manufacturers. It operates through the following segments: On Device Solutions and App Growth Platform. The On Device Solutions segment consists of products and services that simplify the discovery and delivery of mobile apps and content media for device end users. The App Growth Platform segment provides Advertising Solutions and Ad Monetization Solutions. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

Digital Turbines earnings sparked a sharp selloff despite a revenue beat and higher full-year revenue outlook, as traders focused on gross-margin compression and unchanged profit guidance amid increased costs and investment. The community is divided between calling the drop an overreaction to a strong-growth quarter and warning that weaker margins and the debt burden raise concerns about converting growth into profit.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers quarterly report brought a sharp selloff as an unexpected loss, weaker profitability outlook, margin pressure and a sequential subscriber decline overshadowed revenue growth. Traders are split between concerns about execution and profitability and dip-buyers betting that the upcoming Peptides+ launch can support a recovery.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

ASTS is drawing attention after its Q3 report and analyst target cuts, with traders focused on the revenue miss, delayed BlueBird launches and uncertainty around when commercial service can scale. Bulls point to Japan and government funding and the companys partnerships, while skeptics question execution, cash burn and the new rocket program.

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Bridgewater, NJ.

Legend Biotech Corp - ADR

Legend Biotech

Legend Biotechs quarterly report is driving attention: traders cite strong CARVYKTI sales and profitability, but the shares sold off as others focused on slowing growth, flat U.S. sales and managements cautious framing of the 2027 outlook. The reaction is debated as a sell-the-news move after a recent run-up, while some investors are looking ahead to updated LB2501 in-vivo CAR-T data at ASH.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

A strong quarterly earnings beat and raised full-year guidance have put VG in focus, but the muted share-price response has sparked debate over managements emphasis on off-grid AI data-center power. Bulls point to LNG growth and potential short-covering, while skeptics see the AI plans as long-dated and capital-intensive compared with near-term LNG opportunities.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desks quarterly earnings beat and stronger outlook sparked a sharp rally that quickly faded after managements cautious tone and signs of weak underlying growth. Bulls point to the results and expanded buyback authorization as evidence of a turnaround, while bears question the quality and durability of growth and criticize managements credibility.

Lufax Holding Ltd. operates a technology-empowered personal financial services platform. It offers personal lending and wealth management solutions. The company was founded in August 2005 and is headquartered in Shanghai, China.

Lufax Holding Ltd - ADR

A sharp selloff with no confirmed company-specific trigger is driving discussion, as traders speculate about institutional liquidation and weak Chinese consumer-credit conditions. Some holders are averaging down on valuation and a hoped-for recovery in loan quality, while others remain concerned about credit losses, governance, and continued selling pressure.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zetas strong quarterly results and raised outlook are driving attention, with traders also citing bullish analyst upgrades. The community is largely upbeat about growth and improving profitability, but reactions are split over volatile post-earnings trading and whether the stock can sustain its gains.

MercadoLibre, Inc. engages in the development of an online commerce platform with a focus on e-commerce and related services. It operates through the following geographical segments: Brazil, Argentina, Mexico, and Other Countries. The Other Countries segment refers to Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Panama, Peru, Bolivia, Honduras, Nicaragua, El Salvador, Guatemala, Paraguay, Uruguay, and the United States of America. Its products provide a mechanism for buying, selling, and paying as well as collecting, generating leads, and comparing lists through e-commerce transactions. The company was founded by Marcos Eduardo Galperin on October 15, 1999 and is headquartered in Montevideo, Uruguay.

MercadoLibre Inc

MercadoLibre is drawing attention after a post-earnings selloff tied to a profit miss and continued margin pressure, despite strong revenue growth. Traders are divided between buying the pullback on the companys long-term expansion prospects and worrying that heavy investment and credit growth are weighing on profitability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Compared to Estimates, MannKind (MNKD) Q3 Earnings: A Look at Key Metrics

Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

MannKind (MNKD) Reports Q3 Loss, Misses Revenue Estimates

MannKind (MNKD) delivered earnings and revenue surprises of +12.50% and -3.50%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Analysts initiate coverage: RSI Equal-Weight ($22), NWCL Neutral, HDRN Buy.read more...

Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule

MannKind licenses Technosphere GLP-1 tech to Rose Pharma for weight management development.read more...

MannKind Expands Into Weight Loss With Rose Pharma Deal – Here’s What Investors Are Watching

Equity

MannKind and Rose Pharma are partnering to develop an inhaled weight-loss treatment using the Technosphere dry-powder inhalation technology.

FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH

UTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data support its PAH potential.

United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark

UTHR tops Q2 EPS estimates, misses revenues, while advancing Tyvaso and ralinepag programs that reshape future growth.

Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics

The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates

MannKind (MNKD) delivered earnings and revenue surprises of -200.00% and +2.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease

MannKind stock rose after the FDA approved Furoscix ReadyFlow, as the company also announced a $50 million private placement financing.read more...

• Reported GAAP EPS of -$0.01 down -114.29% YoY
• Reported revenue of $101.87M up 24.04% YoY

MannKind posted a Q3 net loss amid increased SG&A, commercial gross margin fell year over year with Furoscix on-body infusor mix, and Tyvaso DPI revenue is highly dependent on UT amid competition.

MannKind's Q3 revenue and commercial product sales increased, Furoscix ReadyFlow received FDA approval and shipments began, while the ralinepag DPI collaboration adds development milestones and potential royalties.

MannKind Corporation (Nasdaq: MNKD) is a commercial-stage biopharmaceutical company with a diversified business spanning marketed products, strategic collaborations and a proprietary development pipeline. Focused on cardiometabolic and orphan lung diseases, MannKind’s portfolio includes Afrezza® (inhaled mealtime insulin), FUROSCIX® (furosemide injection for fluid overload) and V-Go® (all-in-one insulin delivery patch). Its proprietary Technosphere® technology is also utilized in Tyvaso DPI® (an inhaled treatment for pulmonary hypertension), marketed by United Therapeutics. The company is advancing additional inhaled therapies and drug-device combination products designed to address serious unmet medical needs. Founded by Alfred E. Mann in 1991, MannKind is headquartered in Danbury, Connecticut.

Mannkind Corp

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>MannKind will help develop the formulation and provide manufacturing support through the completion of a Phase 1b study.</li><li>MannKind will receive an equity stake in Rose Pharma and potential royalties on future sales.</li><li>Financial terms of the agreement were not disclosed.</li></ul><p>The weight-loss drug market has been dominated by injectable GLP-1 therapies, but MannKind (MNKD) is looking at a different approach. MannKind (MNKD) is pushing into the booming GLP-1 weight-loss market, partnering with Rose Pharma to develop an inhaled treatment using its proprietary Technosphere dry-powder inhalation technology.</p><p><a href="https://stocktwits.com/symbol/MNKD">MNKD shares</a> were up 1.7% at the time of writing in pre-market, tracking a third straight session of gains.</p><h2 class="st-heading-2">What MannKind Gets From The Rose Pharma Deal&nbsp;</h2><p>MannKind and Rose Pharma said they will develop ROSE-010 Technosphere. MannKind will help develop the formulation and provide manufacturing support through the completion of a Phase 1b study.</p><p>In return, it will receive an equity stake in Rose Pharma and potential royalties on future sales. However, the agreement's financial terms were not disclosed.</p><h2>Why Rose Pharma’s ROSE-010 Matters</h2><p>ROSE-010 is designed as a rapid-acting, short-duration treatment. The drug itself has already been evaluated in four human studies. Rose said a previous Phase 2a weight-management study showed reduced calorie intake during meals and weight loss, along with favorable gastrointestinal tolerability.</p><p>“An inhaled therapy with a rapid-acting, short-duration profile could provide patients with greater flexibility and a new way to approach weight management. ROSE-010 Technosphere also has potential application in irritable bowel syndrome, where there is significant unmet medical need for pain relief,” said Enda Kenny, CEO of Rose Pharma.</p><h2 class="st-heading-2">MannKind Has Been Here Before&nbsp;</h2><p>The GLP-1 field isn’t entirely new to MannKind. More than 16 years ago, the company studied MKC253, an inhaled GLP-1 delivered using Technosphere. However, development was halted after a Phase 1 trial.</p><h2 class="st-heading-2">MannKind Builds On Recent Inhaled-Drug Win</h2><p>The deal also comes months after one of MannKind’s biggest recent regulatory victories.&nbsp; In May, the FDA <a href="https://stocktwits.com/news-articles/markets/equity/mnkd-stock-jumps-on-receiving-fda-approval-for-afrezza-to-treat-diabetes-in-children/cZgSyurReMx">approved</a> the expanded use of MannKind’s inhaled insulin Afrezza to children and adolescents aged six and older with diabetes, making it the first and only inhaled mealtime insulin approved for that age group.</p><p>The approval was supported by the Phase 3 INHALE-1 study.</p><h2 class="st-heading-2">MNKD Stock: Retail Mood</h2><p>Meanwhile, retail sentiment surrounding MNKD remained ‘bearish’ over the past 24 hours.&nbsp;</p><p>The stock has shed more than 25% of its value so far in 2026.</p><p><strong>Also read: </strong><a href="https://stocktwits.com/news-articles/markets/equity/oil-traders-short-term-bets-iran-war-morgan-stanley-brent-100/cZt7RmsRJz2"><strong>Oil Traders Are Reportedly Cutting Back On Long-Term Bets As Iran, Ukraine Wars Rage, Morgan Stanley Says – ‘People Have Been More Precise With Their Risk’</strong></a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

MannKind Wants A Piece Of The Weight-Loss Market – But It’s Taking An Inhaled Route

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$4.20
Prev Close	$4.19
Open	$4.18
Dividend Yield	0.00%
50-Day Moving Average	$3.56
Beta	0.87
Avg. Volume	3.82M
PE Ratio	-17.47

52-Week High	$6.51
52-Week Low	$2.23
Market Capitalization	$1.35B
EPS (Annual)	$0.0187
Price to Book	-36.16
Revenue Per Employee	$589,469.59

Feed

News

Sentiment

Earnings

Fundamentals

Info

MNKD Fundamentals